Currently out of the existing stock ratings of Kumaraguru Raja, 35 are a BUY (97.22%), 1 are a HOLD (2.78%).

Kumaraguru Raja

Work Performance Price Targets & Ratings Chart

Analyst Kumaraguru Raja, currently employed at BROOKLINE, carries an average stock price target met ratio of 61.11% that have a potential upside of 92.98% achieved within 560 days. Previously, Kumaraguru Raja worked at ROTH MKM.

Kumaraguru Raja’s has documented 68 price targets and ratings displayed on 18 stocks. The coverage is on Healthcare, Energy sectors.

Most recent stock forecast was given on IMAB, I-Mab at 28-Aug-2025.

Wall Street Analyst Kumaraguru Raja

Analyst best performing recommendations are on FBRX (FORTE BIOSCIENCES).
The best stock recommendation documented was for FBRX (FORTE BIOSCIENCES) at 8/15/2025. The price target of $54 was fulfilled within 341 days with a profit of $42.43 (366.72%) receiving and performance score of 10.75.

Average potential price target upside

of $54.75 (61.19%) on VERU (VERU).
of $42.55 (359.18%) on MNPR (MONOPAR THERAPEUTICS).
of $10.07 (63.32%) on DARE (DARE BIOSCIENCE).

ARCT Arcturus Therapeutics Holdings FBRX Forte Biosciences VERU Veru SCYX Scynexis CLBS Caladrius Biosciences ADIL Adial Pharmaceuticals DRMA Dermata Therapeutics EDSA Edesa Biotech CYCC Cyclacel Pharmaceuticals OTLK OUTLOOK THERAPEUTICS INC BCDA Biocardia CHMA Chiasma CLB Core Laboratories NV DARE Dare Bioscience IMAB I-Mab MNPR Monopar Therapeutics NLSP NLS Pharmaceutics AG RAIN Rain Therapeutics

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Mayank Mamtani (B. RILEY)